Bimuno GOS
Commercial- Indications
- Gastrointestinal disorders, Irritable bowel syndrome
Company intelligence / Profile preview
Clasado Biosciences has developed the most widely studied commercial prebiotic galactooligosaccharide ingredient, Bimuno®, which has demonstrated benefits in gastrointestinal, immune, cognitive health and more. The product portfolio includes both ingredients for formulation partners as well as direct-to-consumer supplements. Over two decades of research have resulted in more than 120 scientific publications and over twenty clinical studies supporting efficacy claims. The company recently expanded into pet nutrition with the launch of Bimuno® Pet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Clasado Biosciences.